Menu

Blood Cell Development Reimagined

A new study is rewriting 50 years of biological dogma by suggesting that mature blood cells develop much more rapidly from stem cells than previously thought.

Nov 9, 2015
Bob Grant

Blood cells, like this basophil and the erythrocytes that surround it, may develop from stem cells in a much simper progression than previously suspected.WIKIMEDIA, HANNA SORENSSONSince 1961, when biologists James Till and Ernest McCulloch discovered the first blood stem cell, researchers have thought that the various mature blood cell types developed from hematopoietic stem cells after a long process of several intermediate steps. But a new study, published last week (November 5) in Science, suggests that the process is much less involved.

“The whole classic ‘textbook’ view we thought we knew doesn't actually even exist,” John Dick, coauthor of the study and a geneticist at the University of Toronto, said in a statement. “Instead, through a series of experiments we have been able to finally resolve how different kinds of blood cells form quickly from the stem cell—the most potent blood cell in the system—and not further downstream as has been traditionally thought.”

Dick and colleagues also discovered that blood cell maturation differs between early development and adulthood, a model that also runs contrary to the previous conception of the process.

“If this work is replicated by other groups, we rewrite the textbooks,” Larry Goldstein, a University of California, San Diego, stem cell researcher who was not involved with the study, told The San Diego Union-Tribune. “First, there’s this very major shift in how blood cells are built from the fetus to the adult, and second, the adult lineage relationships are completely different than what we thought.”

Dick and his colleagues studied about 3,000 human blood cells derived from people of different ages, including umbilical cord blood from infants. They noted that most of the progenitor cells were unipotent and not multipotent as previous models held.

The new findings could be a significant boon to the treatment of blood-related maladies as well as regenerative strategies that aim to use stem cells from patients to develop mature cell populations to introduce back into ailing systems.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.